NCT00693342 2020-02-24
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
GOG Foundation
Phase 3 Withdrawn
Clinical Trials
7 trialsNCT00551265 2017-07-14
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
GOG Foundation
Phase NA Withdrawn
NCT00053235 2015-06-01
Research Study in Patients With Advanced Ovarian Epithelial Cancer
GOG Foundation
Withdrawn
NCT01492920 2014-12-31
Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
GOG Foundation
Phase 3 Withdrawn
NCT00006267 2013-07-09
Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Withdrawn
NCT00369954 2013-06-10
Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
GOG Foundation
Phase 2 Withdrawn
NCT00477867 2013-06-10
Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172
GOG Foundation
Phase NA Withdrawn